Dr. Reddy’s Reports Q2FY27 Results and Senior Management Appointment
Dr Reddys Laboratories Ltd · Outcome · 24 Oct 2026, 12:09 am
Dr. Reddy’s Reports Q2FY27 Results and Senior Management Appointment Dr. Reddy’s Laboratories reported consolidated Q2FY27 revenues of ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ, impacted primarily by lower lenalidomide sales in North America (down 23% YoY). EBITDA stood at ₹17,828 Mn with a 20.6% margin, while PAT attributable to equity holders fell 36% YoY to ₹9,250 Mn. Net cash surplus reached ₹25.0 Bn as of 30th Sep'26. Additionally, the board approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13th Nov'26.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
